These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 973966)

  • 41. The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis.
    el-Raghy I; Back DJ; Osman F; Nafeh MA; Orme ML
    Br J Clin Pharmacol; 1985 Oct; 20(4):313-6. PubMed ID: 4074599
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Quantitative analysis of antipyrine in human blood and saliva using high performance liquid chromatography].
    Doare L; Colin C; Diquet B
    J Chromatogr; 1983 May; 274():403-8. PubMed ID: 6874848
    [No Abstract]   [Full Text] [Related]  

  • 43. [Metabolism of antipyrine during pregnancy].
    Koroleva GA; Semeniuk AV; Kolesnikova LI; Skosyreva GA
    Farmakol Toksikol; 1986; 49(6):92-4. PubMed ID: 3817154
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serial measurements of plasma half-lives and urinary excretion of antipyrine in low-birth-weight infants.
    Murdock AI; Thorgeirsson SS; Rossiger H; Davies DS
    Biol Neonate; 1975; 27(5-6):289-301. PubMed ID: 1174600
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Method of evaluating the activity of enzymes metabolizing drugs].
    Semeniuk AV; Kolesnikova LI; Kulikov VIu; Nedle'kina SV; Salganik RI
    Lab Delo; 1982; (10):31-3. PubMed ID: 6183494
    [No Abstract]   [Full Text] [Related]  

  • 46. Ibuprofen does not impair antipyrine clearance.
    Abernethy DR; Greenblatt DJ
    J Clin Pharmacol; 1983; 23(11-12):517-22. PubMed ID: 6662976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immediate decrease by hydrocortisone of the plasma half-life of antipyrine.
    Breckenridge A; Burke CW; Davies DS; Orme ML
    Br J Pharmacol; 1973 Feb; 47(2):434-6. PubMed ID: 4722054
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antipyrine kinetics in Nigerian women in chronic renal failure.
    Iyun AO; Tucker GT
    Afr J Med Med Sci; 1982 Mar; 11(1):7-9. PubMed ID: 6291357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance.
    Elin RJ; Vesell ES; Wolff SM
    Clin Pharmacol Ther; 1975 Apr; 17(4):447-57. PubMed ID: 1122686
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rapid and simple high-performance liquid chromatographic determination of saliva antipyrine for routine antipyrine test.
    Echizen H; Nakura M; Ishizaki I
    J Chromatogr; 1990 Mar; 526(1):296-9. PubMed ID: 2341543
    [No Abstract]   [Full Text] [Related]  

  • 51. Simplified determination of antipyrine clearance by liquid chromatography of a microsample of saliva or plasma.
    el-Yazigi A; Raines DA; Ali H; Sieck J; Ernst P; Dossing M
    Pharm Res; 1991 Feb; 8(2):269-72. PubMed ID: 2023880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of phenobarbital steady state levels on antipyrine clearance and distribution in the rat.
    Pei YY; Bialer M; Levy RH
    Biopharm Drug Dispos; 1986; 7(1):11-9. PubMed ID: 3955196
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short term anti-tubercular drug therapy and hepatic microsomal enzyme activity. Antipyrine metabolism as an index.
    Hamide A; Sivagnanam G; Raveendran R; Adithan C; Sivaraman V; Chandrasekar S
    J Assoc Physicians India; 1990 Sep; 38(9):631-2. PubMed ID: 2266077
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced antipyrine metabolism in cigarette smokers in Indian population.
    Uppal R; Garg SK; Sharma PR; Nair CR; Chaudhury RR
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):269-71. PubMed ID: 7450928
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Temporal variations of antipyrine half-life in man.
    Vesell ES; Shively CA; Passananti GT
    Clin Pharmacol Ther; 1977 Dec; 22(6):843-52. PubMed ID: 923179
    [No Abstract]   [Full Text] [Related]  

  • 56. Quinine-induced alterations in drug disposition.
    Berlin CM; Stackman JM; Vesell ES
    Clin Pharmacol Ther; 1975 Dec; 18(6):670-9. PubMed ID: 1204275
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors affecting antipyrine metabolism in West African villagers.
    Fraser HS; Bulpitt CJ; Kahn C; Mould G; Mucklow JC; Dollery CT
    Clin Pharmacol Ther; 1976 Sep; 20(3):369-76. PubMed ID: 954356
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of cimetidine on steady state concentration and metabolite formation from antipyrine infused with a rectal osmotic mini pump.
    Teunissen MW; Kleinbloesem CH; de Leede LG; Breimer DD
    Eur J Clin Pharmacol; 1985; 28(6):681-4. PubMed ID: 4065192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antipyrine metabolism during the menstrual cycle.
    Riester EF; Pantuck EJ; Pantuck CB; Passananti GT; Vesell ES; Conney AH
    Clin Pharmacol Ther; 1980 Sep; 28(3):384-91. PubMed ID: 7408398
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.
    Sultatos LG; Dvorchik BH; Vesell ES; Shand DG; Branch RA
    Clin Pharmacokinet; 1980; 5(3):263-73. PubMed ID: 7389235
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.